Core Laboratories (NYSE:CLB) had its target price cut by analysts at Howard Weil from $117.00 to $105.00 in a report issued on Friday, StockTargetPrices.com reports. The firm presently has a “sector perform” rating on the stock. Howard Weil’s price target suggests a potential upside of 17.65% from the stock’s previous close.

A number of other research analysts have also issued reports on CLB. Zacks Investment Research raised Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, January 14th. RBC Capital dropped their price objective on Core Laboratories from $130.00 to $105.00 and set an “outperform” rating on the stock in a report on Thursday. HSBC lowered Core Laboratories from a “hold” rating to a “reduce” rating in a report on Tuesday. KLR Group began coverage on Core Laboratories in a report on Monday, December 14th. They set a “buy” rating and a $155.00 price objective on the stock. Finally, Oppenheimer began coverage on Core Laboratories in a report on Monday, January 11th. They set a “market perform” rating on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $120.73.

Other hedge funds recently modified their holdings of the company. State Board of Administration of Florida Retirement System bought a new stake in shares of Core Laboratories during the fourth quarter valued at about $256,000. MAI Capital Management increased its stake in shares of Core Laboratories by 1.2% in the fourth quarter. MAI Capital Management now owns 4,680 shares of the company’s stock valued at $509,000 after buying an additional 55 shares in the last quarter. Russell Frank Co increased its stake in shares of Core Laboratories by 9.4% in the fourth quarter. Russell Frank Co now owns 885,125 shares of the company’s stock valued at $94,805,000 after buying an additional 75,886 shares in the last quarter. Hutchens Investment Management Inc bought a new stake in shares of Core Laboratories during the fourth quarter valued at about $1,885,000. Finally, Congress Asset Management Co. MA increased its stake in shares of Core Laboratories by 1.3% in the fourth quarter. Congress Asset Management Co. MA now owns 247,825 shares of the company’s stock valued at $26,948,000 after buying an additional 3,079 shares in the last quarter.

Shares of Core Laboratories (NYSE:CLB) traded up 3.71% during mid-day trading on Friday, hitting $92.56. The company’s stock had a trading volume of 153,038 shares. The company has a market cap of $3.94 billion and a PE ratio of 34.58. The stock has a 50-day moving average of $103.01 and a 200-day moving average of $109.68. Core Laboratories has a 12-month low of $84.50 and a 12-month high of $134.87.

Core Laboratories (NYSE:CLB) last released its earnings results on Wednesday, January 27th. The company reported $0.65 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.65. During the same period in the previous year, the firm posted $1.54 EPS. The company earned $182.70 million during the quarter, compared to analyst estimates of $179.48 million. The company’s revenue for the quarter was down 34.4% on a year-over-year basis. On average, equities research analysts forecast that Core Laboratories will post $2.75 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 19th. Shareholders of record on Friday, January 22nd will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Wednesday, January 20th. This represents a $2.20 dividend on an annualized basis and a yield of 2.46%. This is a positive change from Core Laboratories’s previous quarterly dividend of $0.32.

Core Laboratories N.V. (NYSE:CLB) is a provider of proprietary and patented reservoir description, production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

12 Month Chart for NYSE:CLB

Stock Target Prices

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.